Healthcare Professionals

• About DUROLANE
• Classification
• Clinical data
• Benefits of DUROLANE
• Treatment
  • Clinical Procedure
  • Post Treatment
• Algorithms
• Resources
  • Enquiry Form

Clinical data

Single Injection Treatment Regimen

The principal advantage of NASHA^™ is the single-injection treatment regimen, for both knee and hip OA. There are two factors that facilitate this:

• High initial dose of hyaluronic acid
• Extended residence time within the joint.

The high dose is attributable to the physical properties of NASHA. The HA concentration is 20 mg/ml, far higher than other HA preparations, which are 5-10 mg/ml. Thus, every 3 ml injection of DUROLANE delivers 60 mg of HA.

The extended intra-articular residence time of DUROLANE is due to the stabilisation process. Following injection, free HA is gradually released from the gels over an extended period of time.

The outstanding performance of DUROLANE

DUROLANE has been the subject of many published clinical studies, which support the effectiveness, safety and durability of NASHA.

• Prolonged residence time because of the extended
• half-life of 4 weeks¹
• Restored flexibility and pain relief for up to 6 months with the convenience of one office visit^4-7
• Improved mobility and joint function^4-7
• Effective in knee and hip OA^4-7

> Benefits of DUROLANE

References

Ref 1: Lindqvist U, Tolmachev V, Kairemo K, Astrom G, Jonsson E, Lundqvist H. Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;41:603-613.

Ref 2: Synvisc® http://www.fda.gov/cdrh/pdf/p940015.html Synvisc(R) Hylan G-20 File: May 31, 1994.

Ref 3: Brown TJ et al. Exp Physiol 1991; 125-134.

Ref 4: Berg P, Olsson U. Intra-articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: a pilot study. Clin Exp Rheumatol. 2004;22:300-306.

Ref 5: Gerard D, Brocq O, Roux CH, Albert C, Euller-Ziegler L. Intra-articular injection of hyaluronic acid (DUROLANE) for hip osteoarthritis: an open study [abstract]. Abstract FRI0427.

Ref 6: Akermark C, Adalberth T, Ericsater J, Isacsson J. Patient-perceived efficacy of non-animal stabilized hyaluronic acid in the treatment of osteoarthritis of the knee. Poster presented at OARSI 2004.

Ref 7: Akermark C, Berg P, Bjorkman A, Malm P. Non-animal stabilized hyaluronic acid in the treatment of osteoarthritis of the knee - a tolerability study. Clin Drug Invest. 2002;22:157-166.